Device Trial Radar · NCT02061696
ARISTOCRAT-A Randomized Controlled Trial Evaluating Closure Following Access With the AXERA (Device Name) 2 Access System
Last checked: Nov 20, 2026Latest source record: May 23, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
39
Actual
Start
Jan 2014
Primary completion
Dec 2015
Study completion Jan 2016
Sponsor
- Lead sponsor
- Frank SaltielAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Borgess Medical Center; Borgess Cardiology Group; Borgess Heart Center for Excellence
- First posted
- Feb 13, 2014
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of the research study is to observe the clinical safety, effectiveness and patient satisfaction of the AXERA 2 Access System in subjects undergoing coronary angiographic and possible Percutaneous Coronary Intervention (PCI) through the femoral artery when compared to standard manual compression.
Conditions
- Coronary Artery Disease
Interventions
Vascular Access DeviceDevice
AXERA 2 Access System with Reduced Manual Compression
Standard Manual CompressionProcedure
Closure procedure by Manual Compression
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Any Site-Related Major Adverse EventsTime frame: Up to 37 days post procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Borgess Medical Center
Kalamazoo, Michigan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.